These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Long-term tolerability, immunogenicity and efficacy of Nuwiq® (human-cl rhFVIII) in children with severe haemophilia A. Klukowska A, Szczepański T, Vdovin V, Knaub S, Bichler J, Jansen M, Dzhunova I, Liesner RJ. Haemophilia; 2018 Jul; 24(4):595-603. PubMed ID: 29582516 [Abstract] [Full Text] [Related]
28. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review. Hassan S, Cannavò A, Gouw SC, Rosendaal FR, van der Bom JG. J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204 [Abstract] [Full Text] [Related]
29. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Lentz SR, Misgav M, Ozelo M, Salek SZ, Veljkovic D, Recht M, Cerqueira M, Tiede A, Brand B, Mancuso ME, Seremetis S, Lindblom A, Martinowitz U. Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704 [Abstract] [Full Text] [Related]
30. PK-guided personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in adults with severe haemophilia A. Lissitchkov T, Rusen L, Georgiev P, Windyga J, Klamroth R, Gercheva L, Nemes L, Tiede A, Bichler J, Knaub S, Belyanskaya L, Walter O, Pasi KJ. Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151 [Abstract] [Full Text] [Related]
35. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Martinowitz U, Bjerre J, Brand B, Klamroth R, Misgav M, Morfini M, Santagostino E, Tiede A, Viuff D. Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634 [Abstract] [Full Text] [Related]
37. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Mullins ES, Stasyshyn O, Alvarez-Román MT, Osman D, Liesner R, Engl W, Sharkhawy M, Abbuehl BE. Haemophilia; 2017 Mar; 23(2):238-246. PubMed ID: 27891721 [Abstract] [Full Text] [Related]
38. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting. Kruse-Jarres R, Oldenburg J, Santagostino E, Shima M, Kempton CL, Kessler CM, Lehle M, Chebon S, Selak Bienz N, Asikanius E, Mahlangu J. Haemophilia; 2019 Mar; 25(2):213-220. PubMed ID: 30724422 [Abstract] [Full Text] [Related]
39. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. Giangrande P, Andreeva T, Chowdary P, Ehrenforth S, Hanabusa H, Leebeek FW, Lentz SR, Nemes L, Poulsen LH, Santagostino E, You CW, Clausen WH, Jönsson PG, Oldenburg J, Pathfinder™2 Investigators. Thromb Haemost; 2017 Jan 26; 117(2):252-261. PubMed ID: 27904904 [Abstract] [Full Text] [Related]